Skip to main content
Julie R. Park, MD
Julie Park, MD

Julie Park, MD

Member, St. Jude Faculty

  • Chair, Department of Oncology
  • Associate Director Comprehensive Cancer Center, Translational Research
  • Endowed Chair in Pediatric Oncology




  • Fellowship (Leukemia Society of America) - Fred Hutchinson Cancer Research Center, Seattle, Washington
  • Fellowship (Pediatric Hematology/Oncology) – University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington
  • Residency (Pediatrics) – University of Washington, Seattle, Washington
  • MD – University of Vermont, College of Medicine, Burlington, Vermont
  • BA – University of Vermont, College of Arts and Science, Burlington, Vermont

Research Interests

  • Translational research to improve survival of children with cancer
  • Development of cellular immunotherapy trials for pediatric cancer
  • Immuno-oncology
  • Novel cellular immunotherapy for refractory and recurrent pediatric malignancies
  • Neuroblastoma
  • New Approaches to Neuroblastoma Therapy
  • Novel drug development for high-risk neuroblastoma

Honors & Awards

  • 1995  William Guy Forbeck Research Foundation Scholar Award
  • 2003  University of Vermont, Recent Alumni Award
  • 2009  Bushnell Towne Wilkerson Endowed Chair in Pediatric Neuroblastoma
  • 2010  American Pediatric Society
  • 2018  American Society of Pediatric Hematology Oncology Frank Oski Award
  • 2023  Distinguished Academic Achievement Award, The Lerner College of Medicine 

Other Professional Memberships and Experience

Selected Publications

Full list of publications

Pinto N, Naranjo A, Ding X, Zhang FF, Hibbitts E, Kennedy R, Tibbetts R, Wong-Michalak S, Craig DW, Manojlovic Z, Hogarty MD, Kreissman S, Bagatell R, Irwin MS, Park JR, Asgharzadeh S; Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report. Clin Cancer Res Apr 15; 29(8):1546–1556, 2023. 

Goldsmith KC, Park JR, Kayser K, Malvar J, Chi YY, Groshen SG, Villablance JG, Krytska K, Lai LM, Acharya PT, Goodarzian F, Pawel B, Shimada, H, Ghazarian S, States L, Marshall L, Chesler L, Granger M, Desai AV, Mody R, Morgenstern DA, Shusterman S, Macy ME, Pinto N, Schleiermacher G, Vo K, Thurm H, Chen J, Liyangage M, Peltz G, Matthay KK, Berko ER, Maris JM, Marachelian, Mosse YP. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: Phase 1 trial results. Nat Med Apr 3, 2023.: Online ahead of print. PMID 37012551

Vitanza NA, Wilson AL, Huang W, Seidel K, Brown C, Gustafson JA, Yokoyama JK, Johnson AJ, Baxter BA, Koning RW, Reid AN, Meechan M, Biery MC, Myers C, Rawlings-Rhea SD, Albert CM, Browd SR, Hauptman JS, Lee A, Ojemann JG, Berens ME, Dun MD, Foster JB, Crotty EE, Leary SES, Cole BL, Perez FA, Wright JN, Orentas RJ, Chour T, Newell EW, Whiteaker JR, Zhao L, Paulovich AG, Pinto N, Gust J, Gardner RA, Jensen MC, Park JR. Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety. Cancer Discov Jan 9;13(1):114-131, 2023. PMID: 36259971 

Vitanza NA, Ronsley R, Choe M, Henson C, Breedt M, Barrios-Anderson A, Wein A, Brown C, Beebe A, Kong A, Kirkey D, Lee BM, Leary SES, Crotty EE, Hoeppner C, Holtzclaw S, Wilson AL, Gustafson JA, Foster JB, Iliff JJ, Goldstein HE, Browd SR, Lee A, Ojemann JG, Pinto N, Gust J, Gardner RA, Jensen MC, Hauptman JS, Park JR. Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safety. Neoplasia Jan 2;36:100870, 2023. PMID: 36599192 

Matthyssens LE, Nuchtern JG, Van De Ven CP, Gabra HOS, Bjornland K, Irtan S, Stenman J, Pio L, Cross KM, Avanzini S, Inserra A, Chacon JG, Dall'igna P, Von Schweinitz D, Holmes K, Fuchs J, Squire R, Valteau-Couanet D, Park JR, Eggert A, Losty PD, La Quaglia MP, Sarnacki S; Surgical and Medical Committees of SIOPEN*, COG** and GPOH***. A Novel Standard for Systematic Reporting of Neuroblastoma Surgery: The International Neuroblastoma Surgical Report Form (INSRF): A Joint Initiative by the Pediatric Oncological Cooperative Groups SIOPEN*, COG**, and GPOH**. Ann Surg Mar 1;275(3)):e575-e585, 2022. PMID: 32649454

Ceppi F, Wilson AL, Annesley C, Kimmerly GR, Summers C, Brand A, Seidel K, Wu QV, Beebe A, Brown C, Mgebroff S, Lindgren C, Rawlings-Rhea SD, Huang W, Pulsipher MA, Wayne AS, Park JR, Jensen MC, Gardner RA. Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects. Cancer Immunol Res Jul 1;10(7):856-870, 2022. PMID: 35580141 

Desai AV, Gilman AL, Ozkaynak MF, Naranjo A, London WB, Tenney SC, Diccianni M, Hank JA, Parisi MT, Shulkin BL, Smith M, Moscow JA, Shimada H, Matthay KK, Cohn SL, Maris JM, Bagatell R, Sondel PM, Park JR, Yu AL. Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. J Clin Oncol Dec 10;40(35):4107-4118, 2022. PMID: 35839426

Gust J, Rawlings-Rhea SD, Wilson AL, Tulberg NM, Sherman AL, Seidel KD, Wu QV, Park JR, Gardner RA, Annesley CE. GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients. Blood Adv Aug 25:bloodadvances.2022008119, 2022. PMID: 36006611

Park JR, Villablanca JG, Hero B, Kushner BH, Wheatley K, Beiske KH, Ladenstein RL, Baruchel S, Macy ME, Moreno L, Seibel NL, Pearson AD, Matthay KK, Valteau-Couanet D. Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. Cancer Nov 1;128(21):3775-3783, 2022. PMID: 36101004

Asgharzadeh S, Marachelian A, Villablanca JG, Liu WY, Kennedy R, Sposto R, Naranjo A, Tenney S, Yu AL, Ozkaynak MF, Sondel PM, Park JR, Seeger RC. Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy. Pediatr Blood Cancer Sep;69(9):e29719, 2022. PMID: 35441784

DuBois SG, Granger MM, Groshen S, Tsao-Wei D, Ji L, Shamirian A, Czarnecki S, Goodarzian F, Berkovich R, Shimada H, Villablanca JG, Vo KT, Pinto N, Mosse YP, Maris JM, Shusterman S, Cohn SL, Goldsmith KC, Weiss B, Yanik GA, Twist CJ, Irwin MS, Haas-Kogan DA, Park JR, Marachelian A, Matthay KK. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. J Clin Oncol Nov 1;39(31):3506-3514, 2021. Epub 2021 Jul 16.PMID: 34270348

Summers C, Wu QV, Annesley C, Bleakley M, Dahlberg A, Narayanaswamy P, Huang W, Voutsinas J, Brand A, Leisenring W, Jensen MC, Park JR, Gardner RA. Hematopoietic cell transplantation after CD19 CAR T cell-induced ALL remission confers leukemia-free survival advantage. Transplant Cell Ther Oct 10:S2666-6367(21)01295-1, 2021. PMID: 34644605

Irwin MS, Naranjo A, Zhang FF, Cohn SL, London WB, Gastier-Foster JM, Ramirez NC, Pfau R, Reshmi S, Wagner E, Nuchtern J, Asgharzadeh S, Shimada H, Maris JM, Bagatell R, Park JR, Hogarty MD. Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. J Clin Oncol Oct 10;39(29):3229-3241, 2021. doi: 10.1200/JCO.21.00278. PMID: 34319759

Weiss BD, Yanik G, Naranjo A, Zhang FF, Fitzgerald W, Shulkin BL, Parisi MT, Russell H, Grupp S, Pater L, Mattei P, Mosse Y, Lai HA, Jarzembowski JA, Shimada H, Villablanca JG, Giller R, Bagatell R, Park JR, Matthay KK. A safety and feasibility trial of 131 I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study. Pediatr Blood Cancer Oct;68(10):e29117, 2021. doi: 10.1002/pbc.29117. PMID: 34028986

Vitanza NA, Johnson AJ, Wilson AL, Brown C, Yokoyama JK, Künkele A, Chang CA, Rawlings-Rhea S, Huang W, Seidel K, Albert CM, Pinto N, Gust J, Finn LS, Ojemann JG, Wright J, Orentas RJ, Baldwin M, Gardner RA, Jensen MC, Park JR. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat Med Sep;27(9):1544-1552, 2021. doi: 10.1038/s41591-021-01404-8. PMID: 34253928 

Balyasny S, Lee SM, Desai AV, Volchenboum SL, Naranjo A, Park JR, London WB, Cohn SL, Applebaum MA. Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma. JAMA Netw Open Jul 1;4(7):e2116248, 2021. doi: 10.1001/jamanetworkopen.2021.16248. PMID: 34236408 

Granger MM, Naranjo A, Bagatell R, DuBois SG, McCune JS, Tenney SC, Weiss BD, Mosse YP, Asgharzadeh S, Grupp SA, Hogarty MD, Gastier-Foster JM, Mills D, Shulkin BL, Parisi MT, London WB, Han-Chang J, Panoff J, von Allmen D, Jarzembowski JA, Park JR, Yanik GA. Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. Transplant Cell Ther Jun;27(6):490.e1-490.e8, 2021. doi: 10.1016/j.jtct.2021.03.006. PMID: 33823167

Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, Maris JM, Bagatell R, Park JR, Sondel PM. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res Apr 15;27(8):2179-2189, 2021. doi: 10.1158/1078-0432.CCR-20-3909. PMID: 33504555 

Wolpaw AJ, Bayliss R, Büchel G, Dang CV, Eilers M, Gustafson WC, Hansen GH, Jura N, Knapp S, Lemmon MA, Levens D, Maris JM, Marmorstein R, Metallo SJ, Park JR, Penn LZ, Rape M, Roussel MF, Shokat KM, Tansey WP, Verba KA, Vos SM, Weiss WA, Wolf E, Mossé YP. Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers. Cancer Res Apr 1;81(7):1627-1632, 2021. doi: 10.1158/0008-5472.CAN-20-3108. PMID: 33509943 

Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Kraveka JM, Roberts SS, Geiger JD, Doski JJ, Voss SD, Maris JM, Grupp SA, Diller L. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA Aug 27;322(8):746-755, 2019. PMID:31454045

Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK& Valteau-Couanet D. Revisions to the international neuroblastoma response criteria: A consensus statement from the National Cancer Institute clinical trials planning meeting. J Clin Oncol Aug 1;35(22):2580-2587, 2017. PMCID: PMC5676955

Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Kelly-Spratt KS, Hoglund V, Lindgren C, Oron AP, Li D, Riddell SR, Park JR, Jensen MC. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood Jun 22;129(25):3322-3331, 2017. PMID: 28408462

Last update: May 2023